COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Date data sharing statement initially provided
Date results information initially provided
Type of registration
Retrospectively registered

Titles & IDs
Public title
Randomized controlled trial for endovascular intervention for dysfunctional dialysis access with drug-coated balloon versus plain balloon angioplasty
Scientific title
Paclitaxel-eluting balloon Versus plain angioplasty balloon for dysfunctional dialysis access: a prospective double-blinded randomized controlled trial
Secondary ID [1] 289318 0
Nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dysfunctional haemodialysis access 298916 0
Renal failure on haemodialysis 299028 0
Condition category
Condition code
Surgery 298993 298993 0 0
Surgical techniques
Renal and Urogenital 299084 299084 0 0
Kidney disease

Study type
Description of intervention(s) / exposure
Randomised trial where participants with dysfunctional haemodialysis access are assessed by pre-treatment duplex ultrasound. Patients will assessed, counselled and consented by the same vascular team.
They will then be allocated to receiving percutaneous transluminal angioplasty with either paclitaxel coated balloon or plain ( control) balloon.
A single one-off intervention will be performed the same vascular surgeon in the vascular operating theatre in the same hospital. Surgical techniques will be standardised, performed under local anaesthetic, diagnostic angiogram performed and the appropriate sized balloon inflated to 1 minute to nominal pressure. For device failure, further angioplasty is performed with introduction of a high-pressure balloon of appropriate size and inflation to appropriate pressure for three minutes. In case of a flow-limiting dissection, a bare metal nitinol stent of appropriate size is introduced and placed; and in case of a rupture, a covered stent of appropriate size is introduced and placed. A post-procedure angiogram is performed.
Intervention code [1] 294870 0
Treatment: Devices
Comparator / control treatment
Percutaneous transluminal angioplasty with plain angioplasty balloon
Control group

Primary outcome [1] 298461 0
Target lesion primary patency rate at 12 months (functional dialysis access with <50% angiographic re-stenosis and without any repeat interventional procedures)
Timepoint [1] 298461 0
12 months post intervention
Secondary outcome [1] 324210 0
Device Success: Post-procedure angiogram with residual stenosis <30% without high pressure post-dilation
Timepoint [1] 324210 0
Post procedure angiogram is performed intraoperatively, immediately after angioplasty intervention
Secondary outcome [2] 324211 0
Technical success: Post-procedure angiogram final residual stenosis <30%
Timepoint [2] 324211 0
Post procedure angiogram is performed intraoperatively, after angioplasty +/- high-pressure balloon if device failure +/- stent in case of flow-limiting dissection or rupture.
Secondary outcome [3] 324212 0
Clinical success (smooth haemodialysis for 3 consecutive sessions)
Timepoint [3] 324212 0
1-2 week post intervention

Key inclusion criteria
Native arteriovenous fistula or prosthetic arteriovenous graft in the upper limb
Vascular access actively used for hemodialysis
At least 1 previous successful session of hemodialysis via access
Clinical signs of failing access due to presence of significant anatomic stenosis
Detection of elevated venous pressure during dialysis and/or decreased blood flow
Angiographically/sonographically proven venous outflow stenosis >50%
Minimum age
18 Years
Maximum age
80 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
Patient unable to provide informed consent
Patient unable to abide with study follow-up protocol
Patient participating in other relevant or conflicting studies
Vascular access circuit placed in the lower extremities
Bare metal stent or stent graft placed previously
Hemodynamically significant stenosis of the central venous system
Metastatic malignancy or other terminal medical condition
Limited life expectancy (<6 months)
Blood coagulation disorders
Sepsis or active infection
Recent arm thrombophlebitis (<6 months)
Allergy or other known contraindication to iodinated contrast media, heparin, or paclitaxel

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Use of sealed opaque envelopes containing computer-generated random numbers
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
Intervention assignment
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis
A sample size of 17 patients per group is required to detect a difference of 25% in patency rate with a power of 80% and a Type I error of 5 %. With the assumption of 10% loss of follow-up in each group, a sample size of 20 patients per group is required.

Data will be analyzed following intention to treat principle.
Primary and secondary outcomes will be reported as relative risk and 95% confidence intervals. Confounding variables will be controlled by logistic regression.

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment outside Australia
Country [1] 7917 0
Hong Kong
State/province [1] 7917 0
Hong Kong

Funding & Sponsors
Funding source category [1] 293692 0
Name [1] 293692 0
Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong
Address [1] 293692 0
Pamela Youde Nethersole Eastern Hospital
3 Lok Man Road, Chai Wan,
Hong Kong
Country [1] 293692 0
Hong Kong
Primary sponsor type
Department of Surgery, Pamela Youde Nethersole Eastern Hospital, Hong Kong
Pamela Youde Nethersole Eastern Hospital
3 Lok Man Road, Chai Wan,
Hong Kong
Hong Kong
Secondary sponsor category [1] 292525 0
Name [1] 292525 0
Address [1] 292525 0
Country [1] 292525 0

Ethics approval
Ethics application status
Ethics committee name [1] 295129 0
Hong Kong East Cluster Research Ethics Committee
Ethics committee address [1] 295129 0
3 Lok Man Road, Chai Wan, Hong Kong
Ethics committee country [1] 295129 0
Hong Kong
Date submitted for ethics approval [1] 295129 0
Approval date [1] 295129 0
Ethics approval number [1] 295129 0

Brief summary
Dysfunction haemodialysis access is one of the common problems encountered in renal patients. Endovenous intervention with plain balloon angioplasty is one of the common and effective methods to maintain the arteriovenous flow with high success rate. However, the patency rate is low from six months onwards. Repeated interventions on these patients create morbidity and also increases the financial burden on the hospital. Drug eluting balloon may help to reduce the re-stenosis rate and hence lower the morbidity to patients and reduce the cost.

The purpose of this study is to compare the target lesion primary patency rate at 12 months between paclitaxel-eluting balloon (PEB) vs plain balloon angioplasty (BA) for the treatment of venous stenoses of the dysfunctional vascular access patients undergoing haemodialysis
Trial website
Trial related presentations / publications
Public notes
Attachments [1] 905 905 0 0
Attachments [2] 906 906 0 0
Attachments [3] 907 907 0 0
Attachments [4] 908 908 0 0
Attachments [5] 909 909 0 0

Principal investigator
Name 66234 0
Dr Pang Yin Chun, Skyi
Address 66234 0
Department of Surgery
Pamela Youde Nethersole Eastern Hospital
3 Lok Man Road, Chan Wai, Hong Kong
Country 66234 0
Hong Kong
Phone 66234 0
Fax 66234 0
Email 66234 0
Contact person for public queries
Name 66235 0
Dr Pang Yin Chun, Skyi
Address 66235 0
Department of Surgery
Pamela Youde Nethersole Eastern Hospital
3 Lok Man Road, Chan Wai, Hong Kong
Country 66235 0
Hong Kong
Phone 66235 0
Fax 66235 0
Email 66235 0
Contact person for scientific queries
Name 66236 0
Dr Pang Yin Chun, Skyi
Address 66236 0
Department of Surgery
Pamela Youde Nethersole Eastern Hospital
3 Lok Man Road, Chan Wai, Hong Kong
Country 66236 0
Hong Kong
Phone 66236 0
Fax 66236 0
Email 66236 0

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
What data in particular will be shared?
Patient demographics
When will data be available (start and end dates)?
1/10/2019 to 1/12/2020
Available to whom?
Interested parties
Available for what types of analyses?
to achieve the aims in the approved proposal e.g. meta-analysis / systemic reviews
How or where can data be obtained?
Please contact primary author via email
What supporting documents are/will be available?
Study protocol
Ethical approval
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary